个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Advances in research on potential inhibitors of multiple myeloma

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Tang Guoyuan[1] ; Huang Shan[2] ; Luo Ji[3] ; Wu Yingmiao[3] ; Zheng Shuai[3] ; Tong Rongsheng[1,4,*1] ; Zhong Ling[3,5,*2] ; Shi Jianyou[1,4,*1] ;
机构： [1]State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China [2]Cancer Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology ofChina, Chengdu, Sichuan, 610072, China [3]Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People’sHospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China [4]Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University ofElectronic Science and Technology of China, Chengdu, Sichuan, 610072, China [5]Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, Sichuan, 610044, China
出处：
DOI： 10.1016/j.ejmech.2023.115875
ISSN：

关键词： Multiple myeloma Drug resistance Potential drugs Structure-activity relationships

摘要：
Multiple myeloma (MM) is a common hematological malignancy. Although recent clinical applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting antibodies have significantly improved the outcome of MM patient with increased survival, the incidence of drug resistance and severe treatment-related complications is gradually on the rise. This review article summarizes the characteristics and clinical investigations of several MM drugs in clinical trials, including their structures, mechanisms of action, structure-activity relationships, and clinical study progress. Furthermore, the application potentials of the drugs that have not yet entered clinical trials are also reviewed. The review also outlines the future directions of MM drug development.Copyright © 2023 Elsevier Masson SAS. All rights reserved.

基金：
This research was partially funded by the National Natural ScienceFoundation of China (No. 82073311), National Key Research andDevelopment Program of China (No. 2020YFC2005500), Natural Science Foundation of Sichuan Province (No. 2022JDTD0025), ClinicalResearch and Transformation Fund of Sichuan Provincial People’s Hospital (No. 2021LZ03), Open Fund of the State Key Laboratory ofTraditional Chinese Medicine Resources in Southwest China (No.2021HX026), the State Administration of Traditional Chinese Medicine(No. JDZX2015210) and the Open Research Fund of Chengdu Universityof Traditional Chinese Medicine Key Laboratory of Systematic Researchof Distinctive Chinese Medicine Resources in Southwest China (No.2018GZ2011005), Screening and evaluation of anti-hepatic fibrosisvarieties in traditional Chinese medicine formula granules (No.2022HX006), Special Fund of Sichuan Provincial Administration ofTraditional Chinese Medicine (No. 2021MS276), the National NaturalScience Foundation of China (No. 82002212), Sichuan Science andTechnology program (No. 2023NSFSC0538), Special research project ofresearch fund of Sichuan Anticancer Association (Qilu) (No.2022HX040), Scientific research project of cadre health care in SichuanProvince (No. 2023-212), the China Postdoctoral Science FoundationGrant (No. 2019M663567), the foundation of Basic scientific research inCentral UESTC (No. ZYGX2020J024), Medicine-engineering interdisciplinary grant by UESTC (No. ZYGX2021YGLH006), and the OpenResearch Fund of State Key Laboratory of Southwestern Chinese Medicine Resources (No. 2022ZYXK2011011)
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 医学
小类 | 1 区 药物化学
最新[2023]版：
大类 | 2 区 医学
小类 | 1 区 药物化学
JCR分区：
出版当年[2023]版：
Q1 CHEMISTRY, MEDICINAL
最新[2023]版：
Q1 CHEMISTRY, MEDICINAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China
共同第一作者：
通讯作者：
通讯机构： [1]State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China [3]Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People’sHospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China [4]Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, School of Medicine, University ofElectronic Science and Technology of China, Chengdu, Sichuan, 610072, China [5]Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, Sichuan, 610044, China [*1]State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu,611137, China. [*2]Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences &Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China.
推荐引用方式(GB/T 7714)：
Tang Guoyuan,Huang Shan,Luo Ji,et al.Advances in research on potential inhibitors of multiple myeloma[J].EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.2023,262:doi:10.1016/j.ejmech.2023.115875.
APA：
Tang Guoyuan,Huang Shan,Luo Ji,Wu Yingmiao,Zheng Shuai...&Shi Jianyou.(2023).Advances in research on potential inhibitors of multiple myeloma.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,262,
MLA：
Tang Guoyuan,et al."Advances in research on potential inhibitors of multiple myeloma".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 262.(2023)

相关文献

[1]Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. [2]Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma. [3]Perspectives and challenges in developing small molecules targeting purine nucleoside phosphorylase [4]DYRK1A inhibitors for disease therapy: Current status and perspectives. [5]BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions. [6]Pathogenesis and treatment of multiple myeloma. [7]Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma. [8]Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases [9]RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor [10]多发性骨髓瘤疾病全周期健康管理

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号